InnovAtlasMalaria No More
Pharmaceutical and biotech company

Versatope Therapeutics

Develop

Versatope Therapeutics is developing a three-part malaria vaccine using engineered bacterial vesicles designed to prevent infection, disease, and block transmission.

0
Endemic countries
1
U.S. states
2
Products and programs
About

What they do

Versatope Therapeutics is developing a three-part malaria vaccine using engineered bacterial vesicles designed to prevent infection, disease, and block transmission.1 Its U.S. R&D is based in Lowell, Massachusetts.1 The work is at the preclinical development stage, with important leads identified and ready for further development.1

In the United States
Products and programs

In the field and in development

Tri-specific (triple-action at three stages of the malaria parasite life cycle) malaria vaccine3,1
Recombinant extracellular vesicle (REV) platform4,1
Where they work

Partnerships

No endemic-country partnerships are listed.

U.S. partners

Who they work with in the United States

  • NIH/NIAID2,1
    Bethesda/Rockville, MD · Funder · funder — SBIR Phase 2 grant R44AI181242
  • MassVentures2,1
    Boston, MA · Funder · funder — START grant
  • Massachusetts Life Sciences Center5,1
    Waltham, MA · Funder · funder
  • MassChallenge5,1
    Boston, MA
Sources

Where this comes from

  1. 1Confirmed by the organization
  2. 2biospace.com
  3. 3versatope.com
  4. 4versatope.com
  5. 5vcbacked.co